Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.
P/B ratio for Icosavax, Inc. (ICVX)
P/B ratio as of 2022: 1.45
According to Icosavax, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.45. At the end of 2021 the company had a P/B ratio of 1.48.
P/B ratio history for Icosavax, Inc. from 2019 to 2022
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2022 | 1.45 |
| 2021 | 1.48 |
| 2020 | -3.77 |
| 2019 | -43.44 |